Imagine your job is to grow Starbucks. You’ve got your work cut out for you launching hundreds of store locations each year in prime locations. Market research, consumer trends, cost of real estate, these are just a few of the factors you’ll need to analyze before building out the stores, and then you’ve got all the challenges of hiring baristas,
» Read more about: Market Commentary: Is This Stock The Next Starbucks? »
It’s been a while but eventually the wheel has come full circle for Cathie Wood, it seems. From the dizzying heights of 2021 to the crushing lows of 2022, Wood and her ARK Invest fund have enjoyed the highest highs and suffered the lowest lows.
Over the past couple of weeks, sentiment has swung back in her favor and some of her stocks have been on an absolute tear,
» Read more about: Market Commentary: 3 Cathie Wood’s Stocks Are Soaring Again »
Barely a couple of weeks ago, the tenor of the markets changed. Cathie Wood, the poster girl for high growth stocks, reported massive gains among her portfolio of stocks.
In a single week, Nurix Therapeutics gained 16%, Pinterest rose by 19%, Verve Therapeutics flew higher by 18%, Ceres was up 15%, Shopify soared by 22% and Palantir was up 20%.
» Read more about: Market Commentary: 3 Breakouts Signal Santa Claus Rally »
Warren Buffett, the legendary investor and CEO of Berkshire Hathaway, has a track record that speaks for itself. Over the years, his investment decisions have consistently outperformed the broader market by an average factor of 2x annually since he took the helm.
Following its recent earnings report, a standout feature of Berkshire Hathaway now is its substantial cash pile.
» Read more about: Market Commentary: 1 Stock to Buy Above All Others »
Last week, Cathie Wood of ARK Invest had perhaps one of the greatest weeks of her entire investing career. Famous for buying up growth stocks with potentially disruptive innovations, Cathie reported a week that any trader would envy.
Below we highlight eleven charts that reflect just how incredible the performance of her portfolios were,
» Read more about: Market Commentary: 11 Charts That Show Growth Is Back »
It seems that Grayscale’s spot Bitcoin ETF has been in regulatory limbo longer than a Siberian Winter due to the Securities and Exchange Commission’s (SEC) hesitance to green-light it and that’s translating to frenetic moves in crypto once again.
In a recent decision, the SEC was ordered by a U.S. appeals court to review Grayscale’s application for a spot Bitcoin ETF.
» Read more about: Market Commentary: Is It Time To Buy Bitcoin? »
In the world of cybersecurity, Okta is synonymous with secure identity management but even the protector sometimes needs protection. The leader in identity and access management suffered not one but two high-profile breaches over the span of a single year, creating a nightmare scenario for investors.
As a leading cybersecurity company specializing in identity services,
Few investors know that sports apparel giant, Lululemon Athletica, was originally founded as a design studio by day and yoga studio by night. Fast forward to today, and the company is nothing short of a global phenomenon that last week made it into the S&P 500 club.
But what’s on the horizon now for this extraordinary apparel firm?
» Read more about: 1 Sports Apparel Stock Set To Keep Soaring? »
In its latest 13F filing, Berkshire Hathaway bought and sold some stocks that paint a clear picture of what Buffett thinks the future of the economy will look like. Some old favorites he left untouched while others he sold off with abandon. Yet other stocks, he accumulated in spades.
What is Buffett buying and selling now?
» Read more about: Market Commentary: What’s Inside Buffett’s Portfolio? »
Did you know that Eli Lilly and other pharmaceutical companies have sold approximately 10.6 million shots of obesity drug doses in the U.S. in a single month? The rise of these injectable weight loss medications is so powerful that it’s causing investors to question the future of even staple food and beverage stocks.
While this aspect alone could secure Eli Lilly as the pharmaceutical golden goose you’ve been looking for there is much more than meets the eye.
» Read more about: Market Commentary: The Meteoric Rise of Eli Lilly »